PHGE is expected to report earnings to fall 233.29% to -9 cents per share on November 13
Q3'24
Est.
$-0.09
Q2'24
Beat
by $0.16
Q1'24
Beat
by $0.35
Q4'23
Missed
by $0.42
Q3'23
Missed
by $0.03
The last earnings report on August 15 showed earnings per share of 7 cents, beating the estimate of -9 cents. With 124.06K shares outstanding, the current market capitalization sits at 9.25M.
a company, which engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome